Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $15.1900 (2.84%) ($14.7000 - $15.4000) on Fri. Aug. 7, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.19% (three month average) | RSI | 20 | Latest Price | $15.1900(2.84%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX declines -15.4% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(34%) ARKG(33%) ARKK(31%) IBUY(30%) ACES(29%) | Factors Impacting HTBX price | HTBX will decline at least -5.595% in a week (0% probabilities). VXX(-19%) VIXM(-16%) UUP(-13%) UNG(-4%) XLP(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -5.595% (StdDev 11.19%) | Hourly BBV | 0.2 () | Intraday Trend | 0.9% | | | |
|
Inflection Point | Yes | Resistance Level | $15.78 | 5 Day Moving Average | $14.94(1.67%) | 10 Day Moving Average | $15.24(-0.33%) | 20 Day Moving Average | $15.78(-3.74%) | To recent high | -40.1% | To recent low | 193.2% | Market Cap | $1.671b | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |